{"nctId":"NCT00578331","briefTitle":"Safety Study of Olopatadine Nasal Spray","startDateStruct":{"date":"2006-12"},"conditions":["Perennial Allergic Rhinitis"],"count":890,"armGroups":[{"label":"Olopatadine 0.6% Nasal Spray","type":"EXPERIMENTAL","interventionNames":["Drug: Olopatadine 0.6% nasal spray"]},{"label":"Placebo Nasal Spray","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo Nasal Spray"]}],"interventions":[{"name":"Olopatadine 0.6% nasal spray","otherNames":[]},{"name":"Placebo Nasal Spray","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients with confirmed diagnosis of perennial allergic rhinitis who are 12 years and older\n\nExclusion Criteria:\n\n* Age 11 years and younger","healthyVolunteers":false,"sex":"ALL","minimumAge":"12 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Mean Response at Day 30 to the Patient-rated Relief Assessment Questionnaire","description":"Mean Patient-Rated Relief Assessment at Day 30. The patient-rated relief assessment (PRRA) was a 4-point scale with 1=Complete Relief; 2=Moderate Relief; 3=Mild Relief; and 4=No Relief.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.7","spread":"0.9"},{"groupId":"OG001","value":"2.5","spread":"0.9"}]}]}]},{"type":"SECONDARY","title":"Average Number of Days of Rescue Medication Taken","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.2","spread":"22.4"},{"groupId":"OG001","value":"11.8","spread":"26.6"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":15,"n":445},"commonTop":["Epistaxis","Rhinitis","Upper respiratory tract infection","Nasopharyngitis","Sinusitis"]}}}